Session » Rheumatoid Arthritis – Animal Models Poster

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 61

A Human ACPA Monoclonal Antibody Is Preferably Localized at Inflammatory Gingival Tissue and Activates Osteoclastogenensis in Porphyromonas Gingivalis Infected SKG Mouse

9:00AM-11:00AM: Abstract Number: 55

Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice

9:00AM-11:00AM: Abstract Number: 39

Allogeneic Mesenchymal Stem Cells Derived Extracellular Vesicles As a Superior Immunosuppressant in Murine Arthritis Therapy

9:00AM-11:00AM: Abstract Number: 47

Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model

9:00AM-11:00AM: Abstract Number: 35

Arthritis and Atherosclerosis in KRN Ag7 Mice Involve Distinct Inflammatory Cell Populations and Are Independent of CCR2

9:00AM-11:00AM: Abstract Number: 65

Bacteria-Derived Indole Drives Autoimmune Arthritis By Altering B Cell Glycosylation of Autoantibodies

9:00AM-11:00AM: Abstract Number: 33

Card9 Is a Critical Regulator of Autoimmune Arthritis in SKG Mice

9:00AM-11:00AM: Abstract Number: 62

CCR6+CD4+ T Cells Drive IL-23R Signaling-Dependent Progression of Antigen-Induced Arthritis

9:00AM-11:00AM: Abstract Number: 45

CKD-506, First-in-Class Histone Deacetylase (HDAC) 6 Inhibitor, Ameliorates Rheumatoid Arthritis through Regulation of Inflammation and T Cell Function

9:00AM-11:00AM: Abstract Number: 60

Combined Inhibition of Mechanistic Target of Rapamycin and Glutamine Metabolism Inhibits CD4 T Cell Proliferation and Th17 Differentiation, Facilitates the Expansion of Myeloid-Derived Suppressor Cells, and Synergistically Ameliorates Arthritis in SKG Mice

9:00AM-11:00AM: Abstract Number: 56

Comparison of Metabolic Changes in Osteoarthritis and Rheumatoid Arthritis Mouse Models

9:00AM-11:00AM: Abstract Number: 53

Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment

9:00AM-11:00AM: Abstract Number: 31

Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Inflammation and Joint Damage in the TNF-Tg Mouse Model

9:00AM-11:00AM: Abstract Number: 64

Dietary Magnesium Modulates the Intestinal Microbiome and T Cell Subsets

9:00AM-11:00AM: Abstract Number: 37

Discovery of DWP213388, a Potent ITK and BTK Dual Target Inhibitor with Excellent Efficacy, As a Treatment for Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 59

Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model

9:00AM-11:00AM: Abstract Number: 51

Genetic Ablation of Inducible Nitric Oxide Synthase in TNF Transgenic Mice with Inflammatory-Erosive Arthritis Prevents Lymph Node Expansion and Decreases Synovial Infiltrates

9:00AM-11:00AM: Abstract Number: 44

Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 40

IFN Regulatory Factor 3 but Not IFN Regulatory Factor 7 Contributes to Bone Erosion in Collagen Induced Arthritis

9:00AM-11:00AM: Abstract Number: 54

In a Macaque Model of RA By Immunization with Citrullinated Peptides, the Valine in the 11 Position of the DRB1 Molecule Has Greater Impacts on T-Cell Response to Citrullinated Peptides Than the 70-74 Position in the Shared Epitope

9:00AM-11:00AM: Abstract Number: 48

In Vivo Demonstration of Tmtnf Reverse Signaling: Significance in the Therapeutic Response to Anti-TNF Agents during Murine Arthritis

9:00AM-11:00AM: Abstract Number: 58

Inhibition of Lipid Phosphatase SHIP1 Expands Myeloid-Derived Suppressor Cells and Attenuates Rheumatoid Arthritis in Mice

9:00AM-11:00AM: Abstract Number: 52

Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 50

Intra-Articularly Delivering Lentivirus-Based CRISPR Interference Targeting Long Non-Coding RNA H19 in Synovial Fibroblasts Ameliorates Experimental Arthritis

9:00AM-11:00AM: Abstract Number: 34

Microbiome-Drived Aberration of Hematopoietic Stem Cell Development Facilitates Immune Deregulation on the Onset of Collagen-Induced Arthritis in Mice

9:00AM-11:00AM: Abstract Number: 42

Modulation of Autoimmune Arthritis By Protein Tyrosine Phosphatase SHP-1

9:00AM-11:00AM: Abstract Number: 43

Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice

9:00AM-11:00AM: Abstract Number: 46

Organic Dust Inhalants Shift Immune Responses and Extracellular Matrix Balance between Synovium and Lung in the Collagen-Induced Arthritis Mouse Model

9:00AM-11:00AM: Abstract Number: 38

Pre-Clinical Clonally-Expanded aggrecan89-103–Specific CD4+ T Cells Are a Target for Autoimmune Arthritis Prevention

9:00AM-11:00AM: Abstract Number: 57

Repository Corticotropin Injection (H.P. Acthar® Gel) Inhibits Bone Degradation in Rat Adjuvant-Induced Arthritis Model

9:00AM-11:00AM: Abstract Number: 66

Suppression of Inflammatory Arthritis, in Human Paraoxonase 1 Transgenic Mice, Correlates with Upregulation of the Hepatic Glutathione Pathway and Reduction of Bioactive Lipid Mediators

9:00AM-11:00AM: Abstract Number: 32

T Cell-Intrinsic Nod2 Protects Against Th17-Mediated Autoimmune Arthritis in SKG Mice

9:00AM-11:00AM: Abstract Number: 41

TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Improves Bone Strength in Mouse Model for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 36

The Pleiotropic Effects of TAM Signaling on Inflammatory Arthritis in Mice Using Kbxn Serum Transfer Induced Arthritis

9:00AM-11:00AM: Abstract Number: 63

TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 49

Tofacitinib Facilitates the Expansion of Myeloid-Dirived Suppressor Cells and Ameliorates Interstitial Lung Disease in SKG Mice

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].